This CME-certified activity includes faculty review of data presented at the recent Oncology Annual Meeting in Chicago, as well as the current standard of care and ongoing trials. The patient discussion section follows a patient’s journey through diagnosis and treatment, including maintenance therapy, with a focus on the importance of shared decision making.
Edward Garon, MDUCLA Medical Center
Los Angeles, California, United States
Primo N. Lara, Jr, MDUniversity of California Davis Cancer Center
Sacramento, California, United States
Jim BrownOlympia, Washington, United States
- Targeted therapy
- Putting it all together
- Front-line therapy
- Second-line therapy and beyond
- Small cell lung cancer
This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, pulmonologists, pathologists, and other healthcare professionals involved in the treatment of patients with lung cancer.
After successful completion of this educational activity, participants should be able to:
- Evaluate recent data that have the potential to impact practice: including immune checkpoint inhibitors, targeted agents, and treatment strategies
- Identify patients who would most likely benefit from referral to a clinical trial
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by grants from Astellas, Boehringer Ingelheim Pharmaceuticals, Celgene Corporation, Genentech, Lilly, and Merck Sharpe & Dohme Corp.
Developed in collaboration with the Addario Lung Cancer Foundation.
July 15, 2016
July 15, 2017